To find out what adaptations have been made by Inflammatory bowel disease physicians and patients in relation to therapies in flaring IBD patients during severe acute respiratory syndrome 2-COV and what the impact of these is on IBD patients with no symptomatic COVID-19 and in suspected/confirmed COVID-19. Also whether there any IBD related factors impacting the outcome of patients with COVID-19 symptoms or COVID-19 disease
An observational, retrospective, case-controlled study to determine the status of IBD during
development of COVID-19 symptoms/positive COVID-19. The aim is to describe the adaptations in
therapies for active IBD during SARS COV 2 in patients with active IBD and positive or
negative COVID-19 symptoms. It will evaluate IBD outcomes following development of COVID-19
symptoms / positive COVID-19 and determine any predictors of outcomes in IBD patients with
COVID-19 symptoms / positive COVID-19 as well as determine the impact on IBD outcomes
resulting from adaptations to treatments during COVID-19
Inclusion Criteria:
- Patients with IBD +/- flare +/- COVID 19 positivity
Exclusion Criteria:
- Patients below 16
- Patient with inactive IBD
Gastroenterology, Hull Royal Infirmary, Hull University Teaaching Hospitals NHS Trust
Hull, United Kingdom
Shaji Sebastian, Principal Investigator
Hull and East Yorkshire NHS Trust